Ss Innovations International, INC 8-K filings

SS Innovations International announced record second quarter 2026 revenue of $13.9 million, a 39.4% increase year-over-year, driven by strong sales of its SSi Mantra surgical robotic system.

SS Innovations International will showcase its SSi Mantra surgical robotic system at the 2026 Society of Robotic Surgery Annual Meeting, featuring a live kidney telesurgery and multiple breakout sessions.

SS Innovations International, Inc. announced the appointment of Sarah M. Romano as its new Chief Financial Officer, effective August 3, 2026, bringing extensive public company and capital markets experience.

SS Innovations International's subsidiary, SS International Centre for Robotics Surgery, has successfully graduated its inaugural class of 33 participants in a specialized cardiac robotic surgery training program.

SS Innovations International, Inc. has been recognized as the Outstanding Company at the 2026 Surgical Robotics Industry Awards for its advancements in robotic surgery.

SS Innovations International, Inc. has entered into an At-the-Market (ATM) Sales Agreement with Virtu Americas LLC to offer up to $50 million of its common stock.

SS Innovations International, Inc. (SSII) released its June 2026 Company Presentation, highlighting advancements in its SSi Mantra surgical robotic system, global expansion plans, and strong sales growth.

SS Innovations successfully performed the world's longest-distance robotic telesurgery, connecting Guyana and India over 12,500 miles, utilizing its SSi Mantra system.

SS Innovations International, Inc. announced the resignation of Milan Rao as Global Chief Operating Officer and Chief Financial Officer, effective May 25, 2026, with a search for a successor in progress.

SS Innovations International, Inc. announced record first quarter 2026 revenue of $11.1 million, an increase of 116.8% year-over-year, driven by strong growth in SSi Mantra installations and procedures.

SS Innovations International, Inc. successfully demonstrated its SSi Mantra surgical robotic system in a long-distance, cross-border telesurgery event spanning over 4,500 miles.

SS Innovations International announced that over 10,500 cumulative surgeries have been successfully performed using its SSi Mantra surgical robotic system.

SS Innovations International, Inc. announced the unveiling of its vision for several cutting-edge surgical robotic technologies at the 2026 Global Multi-Specialty Robotic Surgery Conference.

SS Innovations International announces the SMRSC 2026 conference in New Delhi, featuring live telesurgeries and the debut of drone-based surgical systems.

SS Innovations secured regulatory approvals for its SSi Mantra surgical robot in Colombia, Oman, Sri Lanka and Kenya, while targeting FDA 510(k) clearance by mid-2026 and an EU CE mark in 2026.

SS Innovations International, Inc. announced preliminary unaudited revenue and operating metrics for Q4 and full year 2025, showing significant growth in SSi Mantra surgical robotic system installations and revenue.

SS Innovations International, Inc. announced the appointment of Milan Rao as Global Chief Operating Officer and Chief Financial Officer, following the resignation of Naveen Kumar Amar.

SS Innovations International, Inc. announced the development of five new 5-millimeter surgical instruments, expanding robotic surgery capabilities for pediatric, cardiac, and head and neck specialties.

SS Innovations International, Inc. announced the publication of an interview with its Chairman and CEO, Dr. Sudhir Srivastava, on Nasdaq's Live From MarketSite.

SS Innovations submitted a 510(k) premarket notification to the FDA for its SSi Mantra surgical robotic system, targeting multiple specialty procedures and the U.S. market.

SS Innovations International, Inc. furnished an updated November 2025 Company Presentation highlighting its advanced surgical robotic system, global expansion, and strong financial growth.

SS Innovations International, Inc. announced the successful completion of the first telesurgery using its compact SSi Mantra Tele Surgeon Console, enhancing remote surgical access.

SS Innovations International, Inc. reported a 192.5% increase in third-quarter 2025 revenue to $12.8 million, driven by strong sales of its SSi Mantra 3 surgical robotic system.

SS Innovations International, Inc. announced its CEO and Chairman will participate in the upcoming UBS Global Healthcare and Stifel 2025 Healthcare Conferences.

SS Innovations International, Inc. reports significant revenue and gross margin growth, expanding its surgical robotics platform globally with key regulatory approvals anticipated.

SS Innovations successfully completed a human factors validation study for its SSi Mantra surgical robotic system and anticipates submitting a 510(k) premarket notification to the FDA in Q4 2025.

SS Innovations International, Inc. has appointed Naveen Kumar Amar as its Chief Financial Officer, effective September 24, 2025, bringing over 27 years of global finance experience.

SS Innovations International, Inc. announced the successful completion of the world's first pediatric pyeloplasty telesurgery using its SSi Mantra surgical robotic system.

SS Innovations International, Inc. successfully performed its first robotic telesurgery from its MantraM mobile unit, advancing accessible surgical care.

SS Innovations International, Inc. announced record second quarter 2025 revenue of $10.0 million, a 121.8% increase, driven by strong SSi Mantra 3 unit sales and significant gross margin expansion.